Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL Inc. (GRAL) is a leader in developing blood-based multi-cancer early detection solutions, most notably through its Galleri® test. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of cancer diagnostics.
Access timely announcements about peer-reviewed study results, partnership developments with leading research institutions, and progress in commercializing early detection technologies. Our curated news collection helps stakeholders track GRAIL’s innovations in methylation-based screening and machine learning applications.
Key updates include coverage of clinical validation studies, FDA regulatory communications, and collaborations with healthcare networks. All content is sourced from official releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to GRAIL’s latest developments in precision oncology. Check back regularly for insights into how the company is advancing its mission to detect cancer at its most treatable stages.
GRAIL (NASDAQ: GRAL) will present new data on its Galleri® multi-cancer early detection (MCED) test at the AACR Annual Meeting in Chicago, April 25-30, 2025. The presentations include real-world evidence from over 100,000 patients, validating the test's capability to detect multiple cancers and accurately predict cancer signal origin.
Key findings include:
- Confirmation of the test's ability to detect cancer signals across various cancer types, particularly those without recommended screening
- Evidence showing reduced cancer risk for one year post-blood draw in patients receiving negative results
- Data supporting annual screening recommendations
- New insights from GRAIL's ctDNA-based targeted methylation platform, demonstrating potential for cancer subtyping through blood samples
GRAIL (NASDAQ: GRAL) has announced the granting of equity awards in the form of restricted stock units (RSUs) to 15 newly hired non-executive employees. The inducement grants, totaling 108,450 shares of GRAIL's common stock, were awarded under the company's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs feature a four-year vesting schedule, with 25% vesting on February 28, 2026, and subsequent annual vestings on the same date, contingent upon continued employment with GRAIL or its subsidiaries.
GRAIL (Nasdaq: GRAL) has launched Generation Possible, partnering with actress Kate Walsh to raise awareness about multi-cancer early detection (MCED) testing. The initiative highlights the significance of early cancer detection, with Walsh's involvement stemming from her parents' cancer experiences.
Key statistics reveal that 46% of Americans aged 50-75 worry about cancer diagnosis, and approximately 70% of cancer deaths are caused by cancers without recommended screening tests. When detected early, the overall 5-year survival rate is four times higher than late-stage diagnosis.
MCED tests serve as a new screening tool for multiple cancers lacking recommended screening tests today. Available at GenPossible.com, the initiative provides resources including Walsh's personal cancer connection, MCED testing information, and a quiz to determine testing appropriateness. These prescription-only tests are recommended for adults with elevated cancer risk, particularly those 50 or older, as a complement to existing cancer screenings.
GRAIL (Nasdaq: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation in Boston on Tuesday, March 4, 2025, at 9:10 a.m. ET.
Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for replay for a minimum of 30 days following the event.
GRAIL (NASDAQ: GRAL) reported strong growth in Q4 and full year 2024, with total revenue increasing 26% to $38.3M in Q4 and 35% to $125.6M for the full year. Galleri® test sales exceeded 137,000 units in 2024, driving U.S. Galleri revenue up 45% year-over-year to $108.6M.
Q4 net loss was $97.1M, including $34.6M in Illumina acquisition-related amortization. Full-year net loss reached $2.0B, primarily due to $1.4B in goodwill and intangible assets impairment. The company ended 2024 with a strong cash position of $767M, extending runway into 2028.
Notable developments include TRICARE Health Insurance adding Galleri as a covered benefit for high-risk patients aged 50+ and a new integration with Quest Diagnostics' ordering system, enabling access through 7,400 patient points nationwide. GRAIL completed study visits for two registrational studies in July and plans to complete its modular PMA submission in H1 2026.
GRAIL (NASDAQ: GRAL) has announced it will release its fourth quarter 2024 financial results after market close on Thursday, February 20, 2025. The healthcare company, focused on early cancer detection, will follow the release with a management-hosted webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET.
The webcast will be accessible through GRAIL's investor relations website at investors.grail.com, with a recorded replay available afterward. Interested parties are advised to register at least ten minutes before the call's scheduled start time through the provided registration link.
GRAIL (NASDAQ: GRAL) and Quest Diagnostics (NYSE: DGX) announced the integration of GRAIL's Galleri® multi-cancer early detection (MCED) test into Quest's test ordering system. This collaboration enables providers to order the Galleri test directly through Quest's Quanum laboratory portal and over 900 electronic health record systems.
The integration makes the test accessible at Quest's 7,400 patient access points nationwide, streamlining the ordering process for over 500,000 healthcare providers. The Galleri test, which detects cancer DNA fragments in blood before symptoms appear, is prescription-only and recommended for adults with elevated cancer risk, particularly those 50 or older.
This development builds upon their existing collaboration since 2021, aiming to improve cancer screening accessibility. The test can detect multiple deadly cancers, including those without current recommended screening tests, which account for nearly 70% of cancer deaths.
GRAIL (NASDAQ: GRAL) published patient-reported outcomes (PRO) from their PATHFINDER study in Lancet Oncology, evaluating patient perspectives on their Galleri® multi-cancer early detection (MCED) blood test. The study assessed participants with cancer signal detected (CSD) and no cancer signal detected (NCSD) over 12 months.
Key findings showed minimal patient distress associated with MCED testing. Most participants with NCSD results reported feeling relieved, while those with CSD results experienced only small negative impacts that returned to baseline within 12 months. The study measured anxiety, distress, uncertainty, health-related quality of life, and satisfaction using three assessment instruments.
High overall satisfaction was reported across all participant groups, regardless of signal detection status. Most participants indicated they were likely to continue with both standard screening and MCED testing in the future.
GRAIL (NASDAQ: GRAL), a healthcare company focused on early cancer detection, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 15 at 9:00 a.m. PT in San Francisco. Interested parties can access both live and replay webcasts through the investor relations section of GRAIL's website at investors.grail.com. The presentation recording will remain available for a minimum of 30 days following the event.
GRAIL (Nasdaq: GRAL) has announced the granting of equity awards to 46 newly hired non-executive employees. The awards consist of restricted stock units (RSUs) totaling 115,093 shares of GRAIL's common stock. These inducement grants were made under GRAIL's Inducement Equity Incentive Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over approximately four years, with 25% vesting on November 30, 2025, and the remaining portions vesting annually thereafter, contingent on continued employment with GRAIL or its subsidiaries.
